When the FDA approved Madrigal's Rezdiffra in 2024, it was the first marketed drug ever for MASH, which affects millions of American adults.

Following a turbulent funding environment, biotechs are seeking to generate more data earlier to reassure investors.

Biogen said that the 60mg cohort saw greater benefit than either of the115mg cohorts. Credit: Tada Images / Shutterstock.com Biogen’s stock has dropped after it released mixed data on its ...

Arrowhead's EU authorisation of Redemplo expands targeted FCS treatment as the competitive apoC-III landscape continues to evolve.

Ipsen claims that Dysport has become the first botulinum toxin therapy to demonstrate efficacy in episodic migraine.

Both AstraZeneca and Ionis’ stocks took a hit at market open on 9 July after the companies announced that a Phase III trial of Wainua (eplontersen) in transthyretin-mediated amy ...

If approved, Keenova's Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.

Teva plans to start a Phase IIb study on TEV-‘408 in vitiligo during the final quarter of 2026 following positive results of a Phase Ib trial.

Kailera Therapeutics’ bet on Hengui Pharma’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA) appears to be paying off following two late-stage wins in obesity and type ...

More positive Phase II data from a subgroup further supports the trial expansion, which will lead further development.

Brii Bio has reported topline EOT data from its ongoing Phase IIb ENRICH and ENHANCE trials assessing sequential and concurrent use of BRII-179, elebsiran, and PEG-IFNα to treat chronic HBV infection.